Silo pharma announces positive results in alzheimer's disease study

Preclinical study shows spc-14's effectiveness against lh (luteinizing hormone) stress, helplessness, and anxiety. sarasota, fl, jan. 24, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its alzheimer's disease therapeutic spc-14 showed positive efficacy in small animals.
SILO Ratings Summary
SILO Quant Ranking